Clinical information: (b)(6), patient site id: (b)(6).It was reported that on (b)(6) 2022, a 27mm sjm masters series valsalva aortic valved graft was implanted.There were no adverse intraprocedural events reported.On (b)(6) 2022, the patient developed post-operative bleeding due to the operation.The patient was returned to surgery, and it was noted that the bleeding was coming from the graft anastomosis.The bleeding was stopped.The patient's hemoglobin was 4.6 mmol/l, and the patient received 3 units of red blood cells (rbc), 2 units of platelets, and 3 units of plasma.On (b)(6) 2022, the patient developed atrial fibrillation, which was treated with amiodarone.The atrial fibrillation resolved on (b)(6) 2022.On (b)(6) 2022, hemoglobin was 5.0 mmol/l, and the patient received one unit of rbc.On (b)(6) 2022, the patient was re-admitted to the hospital due to hypervolemia, which was treated with diuretics and was resolved by (b)(6) 2022.
|
An event of bleeding after the implant procedure was reported.It was also reported that three days after the implant procedure the device history record was reviewed to ensure that each manufacturing and inspection operation was performed and the product met all specifications information from the field indicated the bleeding was due to the operation and that the bleeding was coming from the graft anastomosis.There is no indication of a product quality issue with regards to manufacture, design, or labeling.
|